AR and prostate cancer: 5α‐dihydrotestosterone (DHT), the cognate ligand of androgen receptor (AR), has been shown to activate matriptase to promote prostate cancer cell invasion and metastasis.7, 8 This prompted us to explore the effects of some natural and synthetic ligands of nuclear receptors on matriptase expression and activation.